Biosergen to welcome two new board members based on election at the Annual General Meeting
Stockholm, Sweden – June 11, 2024 – Based on the change in ownership during successful capital raise earlier this year major shareholders in Biosergen AB (Biosergen) present a proposal for the election of the board of directors ahead of the annual general meeting 2024
Ahead of the annual general meeting in Biosergen to be held on Friday, June 14, 2024, major shareholders propose changes to the current board composition. Major shareholders propose that new member Anna Ljung is elected as chairperson of the board for the period until the end of the annual general meeting in 2025 and that current member Marianne Kock is elected as deputy chairperson of the board for the same period. Furthermore, major shareholders have proposed that Robert Molander is newly elected as ordinary board member and that Mattias Klintemar is re-elected as ordinary board member, both also for the period until the end of the annual general meeting in 2025.
Current board members Torsten Goesch, Achim Kaufhold, Henrik Moltke have declined re-election.
Information about the new Board Members
Anna Ljung
CEO of Moberg Pharma AB since 2019, before that she was the CFO of the company. Anna Ljung has more than 20 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB and as independent technology licensing consultant. In addition to serving as CEO of Moberg Pharma, she also currently serves as Board member of Saniona AB and ADDvise Group AB.
Robert Molander
Senior executive and advisor with over 25 years of expertise in life science commercialization, primarily based in the United States. Robert has successfully led companies such as Novartis, Pfizer, Shionogi, and Trialbee through product launches, business development and scaling commercial operations. Robert has previously been Chief Commercial Officer at Infant Bacterial Therapeutics AB and Trialbee AB and a board member of Infant Bacterial Therapeutics AB. Robert is currently Board member of Xspray Pharma AB, CEO of Stratfox Healthcare Group LLC.
Tine Olesen, CEO of Biosergen commented on the adjustment of the Biosergen board: Biosergen has so far had a very active board with excellent experience in early stage development. We have been blessed with knowledgeable and experienced board members. We would like to thank each one of them for the guidance and decision over the years, it has been crucial for Biosergen. Also, we would like to welcome the new board members to the Biosergen family and we hope for a fruitful collaboration in the future. We are entering a later stage of the development and we hope to benefit of the new two board members’ experience.
Information on the board members who are proposed for re-election can be found in the annual report and at the company website www.biosergen.net.
For further information about Biosergen, please contact:
Tine Olesen, CEO
Telephone: +45 3135 5707
E-mail: tine.olesen@biosergen.net
Niels Laursen, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).
ABOUT BIOSERGEN
Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen’ s mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immune-compromised cancer- transplant- and AIDS patients every year.